The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)

A randomized phase II/III study to evaluate the safety and efficacy of disitamab vedotin (DV) plus toripalimab and chemotherapy/trastuzumab as first-line treatment for HER2-expressed, locally advanced, or metastatic gastric cancer.

Lin  Shen

Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; MSD; SERVIER; Transcenta Holding Limited

Research Funding - BeiGene (Inst)

Guoliang  Ding

No Relationships to Disclose

Dan  Feng

No Relationships to Disclose

Jianmin  Fang

Employment - RemeGen Biosciences Inc. (I)

Leadership - RemeGen Co. Ltd.

Stock and Other Ownership Interests  - RemeGen Co. Ltd.